Antitumor activity
ANL
A total of 44 patients were involved in the efficacy analysis (efficacy-evaluable population), with 22 cases in the ANL group and 22 cases in the ANL+S-1 group. In the ANL group, 1 (4.5%) patient achieved a PR, but none achieved a CR. The ORR was 4.5% (1/22), and the DCR was 77.3% (17/22). The median PFS was 4.2 months (95% CI, 3.6–6.0) (Comparison of progression-free survival (PFS) between the anlotinib (ANL) group and ANL+S1 group.Comparison of overall survival (OS) between the anlotinib (ANL) group and the ANL+ S1 group.